[go: up one dir, main page]

MX2016006460A - Uso del peptido gk-1 como un agente anti-tumoral y/o anti-metastasico. - Google Patents

Uso del peptido gk-1 como un agente anti-tumoral y/o anti-metastasico.

Info

Publication number
MX2016006460A
MX2016006460A MX2016006460A MX2016006460A MX2016006460A MX 2016006460 A MX2016006460 A MX 2016006460A MX 2016006460 A MX2016006460 A MX 2016006460A MX 2016006460 A MX2016006460 A MX 2016006460A MX 2016006460 A MX2016006460 A MX 2016006460A
Authority
MX
Mexico
Prior art keywords
antitumoral
peptide
cancer
antimetastatic agent
treatment
Prior art date
Application number
MX2016006460A
Other languages
English (en)
Other versions
MX385094B (es
Inventor
Del Carmen Fragoso González Gladis
Álvaro Segura Velázquez René
Lydia Sciutto Conde Edda
TORRES GARCÍA Diana
Brenda Cervantes Torres Jacquelynne
Pérez Torres Armando
Manucharyan Karen
Original Assignee
Univ Nacional Autónoma De México
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Nacional Autónoma De México filed Critical Univ Nacional Autónoma De México
Priority to MX2016006460A priority Critical patent/MX385094B/es
Priority to EP17799725.1A priority patent/EP3459557B1/en
Priority to US16/302,786 priority patent/US11020449B2/en
Priority to PCT/MX2017/000055 priority patent/WO2017200369A2/es
Publication of MX2016006460A publication Critical patent/MX2016006460A/es
Publication of MX385094B publication Critical patent/MX385094B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1767—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere al uso del péptido que presenta la secuencia de aminoácidos G-Y-Y-Y-P-S-D-P-N-T-F-Y-A-P-P-Y-S-A denominado GK-1 para su uso como un agente antitumoral y antimetátasica o para el tratamiento de cáncer específicamente de células cancerosas de células basales, de células escamosas, carcinoma de células de transición y adenocarcinoma, y de preferencia para el tratamiento de cáncer de mama.
MX2016006460A 2016-05-18 2016-05-18 Uso del péptido gk-1 como un agente anti-tumoral y/o anti-metastásico. MX385094B (es)

Priority Applications (4)

Application Number Priority Date Filing Date Title
MX2016006460A MX385094B (es) 2016-05-18 2016-05-18 Uso del péptido gk-1 como un agente anti-tumoral y/o anti-metastásico.
EP17799725.1A EP3459557B1 (en) 2016-05-18 2017-05-18 Use of the gk-1 peptide as an antitumoral and/or antimetastatic agent
US16/302,786 US11020449B2 (en) 2016-05-18 2017-05-18 Use of the GK-1 peptide as an antitumoral and/or antimetastatic agent
PCT/MX2017/000055 WO2017200369A2 (es) 2016-05-18 2017-05-18 Uso del péptido gk-1 como un agente anti-tumoral y/o anti-metastásico

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
MX2016006460A MX385094B (es) 2016-05-18 2016-05-18 Uso del péptido gk-1 como un agente anti-tumoral y/o anti-metastásico.

Publications (2)

Publication Number Publication Date
MX2016006460A true MX2016006460A (es) 2017-11-17
MX385094B MX385094B (es) 2025-03-14

Family

ID=60325378

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016006460A MX385094B (es) 2016-05-18 2016-05-18 Uso del péptido gk-1 como un agente anti-tumoral y/o anti-metastásico.

Country Status (4)

Country Link
US (1) US11020449B2 (es)
EP (1) EP3459557B1 (es)
MX (1) MX385094B (es)
WO (1) WO2017200369A2 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025159780A1 (en) * 2024-01-25 2025-07-31 Verrica Pharmaceuticals Inc. Administration of an anti-cancer peptide

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA05003413A (es) * 2005-03-31 2007-02-22 Univ Mexico Nacional Autonoma Uso del peptido gk-1 para potencial la respuesta inmunologica generada por la vacuna de influenza.
MX352522B (es) * 2011-07-26 2017-11-15 Univ Mexico Nac Autonoma USO DE PEPTIDO Gk-1 EXPRESADO EN EL FAGO FILAMENTOSO M13 PARA LA ELABORACION DE PRODUCTOS FARMACEUTICOS QUE AUMENTAN LA EFICIENCIA DE LA RESPUESTA INMUNE INDUCIDA POR ANTIGENOS VACUNALES O PATOGENOS.

Also Published As

Publication number Publication date
WO2017200369A3 (es) 2018-01-11
EP3459557A4 (en) 2019-10-02
EP3459557B1 (en) 2022-04-27
EP3459557A2 (en) 2019-03-27
US20200222495A1 (en) 2020-07-16
US11020449B2 (en) 2021-06-01
WO2017200369A2 (es) 2017-11-23
MX385094B (es) 2025-03-14

Similar Documents

Publication Publication Date Title
PH12021553000A1 (en) Multispecific proteins
MY203971A (en) Anti-lag-3 antibodies and compositions
NZ732211A (en) Combination immunotherapy approach for treatment of cancer
MX2017004691A (es) Bloqueo de cd73.
PH12015501983A1 (en) Peptides and compositions for treatment of joint damage
MY186712A (en) Methods and compositions for inhibiting the interaction of menin with mll proteinss
GEP20217326B (en) Constructs having a sirp-alpha domain or variant thereof
ZA201802966B (en) Peptides and peptidomimetics in combination with t cell activating and/or checkpoint inhibiting agents for cancer treatment
MX2016016337A (es) Polipeptidos apelina.
PH12021551036A1 (en) Anti-liv1 immune cell cancer therapy
MX2018010295A (es) Anticuerpos que tienen especificidad para atenuador de linfocitos b y t (btla) y usos de los mismos.
TR201808169T3 (tr) Rekombinant probiyotik bakteriler .
EA201692529A1 (ru) Способы и композиции для лечения расстройств с использованием фоллистатиновых полипептидов
EP4353319A3 (en) Methods of adoptive cell therapy
MX2020003219A (es) Anticuerpos que tienen especificidad para btn2 y usos de los mismos.
MX2017010883A (es) Composicion para el tratamiento de la infertilidad.
PH12017500853B1 (en) Cd44v6-derived cyclic peptides for treating cancers and angionesesis related diseases
PH12021550122A1 (en) Solubilized apyrases, methods and use
MX2020012782A (es) Inhibidor de ccr5 para el uso en el tratamiento de cancer.
MX2020002585A (es) Inhibidor de hdac combinado con un modulador del punto de control inmunitario para la terapia contra el cancer.
MX2020000636A (es) Proteinas sinteticas y usos terapeuticos de las mismas.
ZA202106807B (en) Antibodies having specificity for btn2 and uses thereof
PH12020550795A1 (en) Methods of using and compositions containing dulaglutide
PH12019500344A1 (en) Immunotherapy for polyomaviruses
MX2019014090A (es) Métodos para el tratamiento de la reservoritis crónica.